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Background: Individuals with pain often present with more than one painful condition. The 
purpose of this study was to characterize the rates of comorbidity, pain medication use, and 
health care costs for 23 selected pain conditions in a large health plan using administrative 
claims data from 2005 to 2007.
Methods: Eligible patients included 1,211,483 adults with at least one pain condition during 
the one-year study period. Pain condition cohorts were classified based on the first diagnosis 
present in the claims during the study period.
Results: Musculoskeletal pain conditions were among the most prevalent cohorts including 
low back pain, osteoarthritis, and fibromyalgia. Cancer pain was the least prevalent cohort. 
  Conditions with the lowest illness severity included migraine and painful bladder syndrome 
cohorts, while cohorts with diabetic neuropathy, human immunodeficiency virus (HIV)-  associated 
pain, and cancer pain were the most severe. Across cohorts, the mean number of comorbid pain 
conditions ranged from 1.39 (for cancer pain and migraine) to 2.65 (for multiple sclerosis pain). 
High rates of mental health conditions were found in cohorts with HIV-associated pain and 
multiple sclerosis pain (42.59% and 34.78%) and were lowest among cohorts with rheumatoid 
arthritis and psoriatic arthropathy (12.73% and 13.31%), respectively. Rates of sleep disorders 
ranged from 5.47% (for painful bladder syndrome) to 11.59% (for multiple sclerosis pain). 
Overall, patients averaged 3.53 unique pain medications during the study period. Considerable 
annual total health care costs were observed in the cancer pain cohort and the lowest costs were 
observed in the postherpetic neuropathy, surgically-induced pain, migraine, and irritable bowel 
syndrome cohorts. Costs attributed to pain were highest among the multiple sclerosis, HIV , and 
cancer pain cohorts. The highest pharmaceutical costs were observed in the HIV cohort.
Conclusion: These findings underscore the heterogeneity of patients with pain in terms of  burden of 
illness, costs to the health care system, and the complexity of commonly co-occurring disorders.
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Introduction
Pain is the leading reason for patients seeking medical care1 and is one of the most 
disabling, burdensome, and costly conditions in the US. Overall, pain care/treat-
ment and lost productivity costs US$635 billion per year.2 One study estimated that 
common pain conditions result in an additional estimated $61 billion annual loss in 
productivity among active US workers (US dollars for 2002).3 An increased rate of 
chronic pain has been associated with being female, older, and leaving the workforce 
earlier through retirement or sick leave. Females aged 50–64 years who retired early 
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were estimated to have a 91.1% prevalence of chronic 
pain.4 Given the aging US population and the unsustainably 
increasing percentage of the US gross domestic product 
devoted to health care, there is a clear and imminent need 
for valid health care economic evaluation data to establish 
health care funding priorities, including for chronic pain 
treatment modalities.
Chronic pain accompanies a variety of diseases and 
occurs across the entire life span. Individuals with multiple 
chronic conditions have been found to have higher health care 
expenditures, including some avoidable medical care costs.5 
To improve the research and management of pain, greater 
understanding is needed on the heterogeneity of patients with 
pain, yet epidemiological and clinical research traditionally 
imposes constraints that prevent us from assessing the holistic 
view of a patient with pain. Either studies look broadly at the 
severity or impact of pain in global terms or, if a condition is 
examined, pain related to other conditions is often excluded 
(eg, all chronic pain).
Several studies have identified the strong association 
between the presence of chronic pain and mental health 
conditions, such as depression,6–9 anxiety,10 or mental 
health in general.4 For example, the association between 
depression and chronic pain has been well studied.7 In a 
systematic literature review, 65% of patients with depres-
sion experienced pain.7 This review concluded that patients 
with moderate to severe pain were more likely to experi-
ence greater symptoms of depression, nonresponsiveness to 
treatment for depression, and worse depression outcomes, 
such as lower quality of life and decreased work function. 
Other studies found an increase in health care resource uti-
lization and costs associated with patients with depression 
and pain relative to patients with either condition alone.9,11 
Results from a survey of 17   countries found that, as the 
number of pain complaints increased, so did the likelihood 
of mood or anxiety   disorders.12   Depression has been found, 
in numerous studies, to co-occur with spinal cord injury and 
many other conditions, including osteoarthritis and diabetic 
neuropathy.13
Pain has also been associated with sleep disorders14 and 
complex chronic illnesses such as heart failure and   diabetes.15 
Osteoarthritis has been observed to coexist with other con-
ditions in over 90% of patients, these conditions include 
cardiovascular, respiratory, gastrointestinal, urogenital, 
endocrine, metabolic, and neurological diseases, as well as 
diseases of the ear, eye, throat, and larynx.16 Neuropathic 
pain conditions have also been found to occur with sleep 
disturbances, as well as depression and anxiety.17
Less is known about the rates of multiple pain   diagnoses. 
The presence of pain is believed to cause individuals to 
be more susceptible to pain in other areas.18 This may be 
explained by central sensitization theory, which purports cells 
of neurons change following a prolonged pain stimulus.18 
These changes increase the responsiveness of the neurons 
and lowered pain thresholds following repeated stimulation.18 
Research to date has been limited to specific pain conditions 
and other pain comorbidities, and headache and migraine, and 
the pain comorbidities that occur with those specific condi-
tions have been the focus of the available literature.19,20
Because patients with pain attributed to various condi-
tions may be quite diverse across demographic and clinical 
experiences, we aimed at looking holistically at the comor-
bidities associated with each cohort of patients. Therefore, 
the purpose of this study was to characterize the rates of 
comorbidity, pain medication use, and health care costs for 
selected pain conditions in a large health plan using admin-
istrative health claims data. We identified the most prevalent 
types of pain conditions, as well as pain medication use 
and direct health care costs associated with selected pain 
  conditions. This study also allowed us to compare distinct 
pain categories and individual pain diagnoses descriptively 
within a single data source.
Materials and methods
Data source
Thomson Reuters’ MarketScan United States Commercial 
and Medicare Supplemental retrospective claims databases 
covering the years 2005–2007 were used to address the study 
objectives. These databases contain national, employer-
based insurance claims for active and retired employees and 
their dependants. While the databases are not considered 
to be nationally representative, the data do include those in 
various sociodemographic groups and geographies across 
the US. Data consist of person-specific information on 
enrollment, medical, and pharmacy claims. Enrollment data 
included monthly enrollment status and demographic infor-
mation such as age and gender. Age was assessed as both a 
continuous and dichotomous variable in order to examine 
the subpopulation that was 65 years and older. Medical 
claims provided facility and provider specialty categories, 
diagnosis codes based on the International Classification 
of Diseases, 9th Edition (ICD-9), provider payments, and 
dates of service.   Prescription drug claims included National 
Drug Codes, number of days supplied, prescription fill dates, 
and payments. Line of therapy was defined by the order in 
which medications were prescribed subsequent to the initial 
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diagnosis date. All data are de-identified but linkable with 
encrypted patient identifiers to remain compliant with the 
Health Insurance Portability and Accountability Act.
Study sample and cohorts
Patients met the study inclusion criteria if they were diag-
nosed with at least one of the selected pain conditions 
between January 1, 2006 and December 31, 2006 (the index 
period) and had two years of continuous pharmaceutical 
and medical benefit enrollment between January 1, 2005 and 
December 31, 2007. This allowed for one year prior to and 
one year following the first pain diagnosis during the index 
period (index diagnosis). Patients were 18 years of age or 
older at the time of the index diagnosis. The final sample 
included 1,211,483 patients with pain conditions.
To quantify the percentage of patients with unique pain 
types, patients were classified into 23 individual pain con-
ditions based on the ICD-9 code for the index diagnosis. 
These include pain conditions that are considered chronic 
(typically, lasting longer than three months). If more than 
one selected pain condition was present during the first claim, 
patients were categorized according to the primary diagnosis. 
If there was more than one primary diagnosis, patients were 
placed into the cohorts of primary interest for this study in 
the order in which the indications appear in Table 1. Table 1 
depicts the counts and ICD-9 definitions for the 23 specific 
pain conditions.
To address the objective of characterizing the rates of 
comorbidity for 23 selected pain cohorts, the Charlson 
Comorbidity Index and the Chronic Disease Score vari-
ables were constructed. The Charlson Comorbidity Index 
assesses comorbidity level by taking into account both the 
number and severity of diagnoses available from the medical 
records. A higher score has been validated to be predictive 
of outcomes such as function, hospital length of stay, and 
mortality rates. The Chronic Disease Score uses a variation 
in the algorithm to measure severity of comorbidity measures 
of overall sickness.
The presence of comorbidities in each of the 23 pain 
cohorts was assessed for other concurrent pain conditions, 
mental health, and sleep disorders. To be considered comor-
bid, the co-occurring condition defined through ICD-9 claims 
Table 1 Pain condition cohorts: definition and sample size
Pain cohort ICD-9 definitions n %
Diabetic neuropathy 250.6, 357.2 37,133 3.07%
Postherpetic neuropathy 053.10, 053.11, 053.12, 053.13, 053.14, 053.19 3551 0.29%
Trigeminal neuralgia 350.1 3869 0.32%
hIV-associated pain hIV (042, 079.53, 795.71, V08) and other chronic pain (338.29),  
chronic pain syndrome (338.4) or generalized pain (780.96)
371 0.03%
Stroke-associated pain Stroke (430–434.9, 436–437.9) and central pain syndrome (338.0) 3087 0.25%
Lumbar radiculopathy 724.4 56,358 4.65%
Complex regional pain syndrome 337.2 1808 0.15%
Spinal cord injury Spinal cord injury without evidence of spinal bone injury (952)  
and 338.29, 338.4, 780.96
331 0.03%
Surgically-induced pain Other acute postoperative pain (338.18), other chronic postoperative pain 
(338.28)
1478 0.12%
Phantom limb 353.6 205 0.02%
Cervical radiculopathy Cervical radiculitis (723.4) 40,844 3.37%
Multiple sclerosis-associated pain 340 and central pain syndrome (338.0) 647 0.05%
Fibromyalgia 729.1 75,570 6.24%
Osteoarthritis 715.0, 715.1, 715.2, 715.8, 715.9, 721.0, 721.1, 721.2, 721.3,  
721.41, 721.42
365,086 30.14%
Low back pain 722.83, 724.02, 724.2, 724.5, 724.8 424,410 35.03%
Migraine 346.0, 346.1, 346.2, 346.8, 346.9 92,943 7.67%
Rheumatoid arthritis 714.0, 714.1, 714.2, 714.30, 714.31, 714.32, 714.33, 714.4, 714.81 40,362 3.33%
Ankylosing spondylitis 720.0, 720.1, 720.2, 720.81, 720.89 10,050 0.83%
Psoriatic arthropathy 696 4795 0.40%
Cancer pain 338.3 28 0.00%
Irritable bowel syndrome 564.1 40,025 3.30%
Painful bladder syndrome Urinary frequency (788.41) with other specified symptoms  
associated with female genital organs (625.8) or unspecified  
symptoms associated with female genital organs (625.9)
2870 0.24%
Interstitial cystitis 595.1 5662 0.47%
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had to be present during the one-year follow-up period. 
Pain comorbidities were defined using the same 23 condi-
tions, but occurring after the index pain diagnosis. Mental 
health conditions were categorized into any mental health 
condition, as well as categories of major depressive disorder 
(296.2, 296.3), other depressive symptoms (311), anxiety 
(300.0, 300.1, 300.2, 300.3–300.7, 300.8), and other psychi-
atric conditions (293, 294, 297, 298, 299, 316, 780.02, 780.1, 
780.50, 780.52, 780.54–780.56, 780.58, 780.59). The rates of 
any mental health condition and the mean number of mental 
health conditions were assessed. Any mental health condi-
tion included patients with major depressive disorder, other 
depressive symptoms, anxiety, other psychiatric conditions, 
and a host of other conditions including dementias (290), 
schizophrenic disorders (295), personality disorders (301), 
sexual and gender identity disorders (302), physiological 
malfunction arising from mental factors (306.7–306.9), spe-
cial symptoms or syndromes, not elsewhere classified (307.3, 
307.4, 307.5, 307.6, 307.7, 307.80, 307.89, 307.9), acute 
reaction to stress (308), adjustment reaction (309), specific 
nonpsychotic mental disorders due to brain damage (310), 
disturbance of conduct not elsewhere classified (312), dis-
turbance of emotions specific to childhood and adolescence 
(313), hyperkinetic syndrome of childhood (314), specific 
delays in development (315), mental retardation (317, 318, 
319), organic sleep disorders (327.0–327.1), chromosomal 
anomalies (758.0–758.2, 758.3), other symbolic dysfunc-
tion (784.6), senility without mention of psychosis (797), 
nervousness (799.2), and observation for suspected mental 
condition (v71.01, v71.02, v71.09). Comorbid sleep condi-
tions included specific disorders of sleep of nonorganic origin 
(307.4), sleep disturbances (780.5), organic sleep disorders 
(327), cataplexy and narcolepsy (347), and lack of adequate 
sleep (v69.4).
Descriptors of pain medication use included the number 
of unique pain medications prescribed, line of therapy, and 
length of therapy. Pain medications were defined as antide-
pressants (selective serotonin reuptake inhibitors, serotonin 
norepinephrine reuptake inhibitors, tricyclic antidepres-
sants, others), anticonvulsants, analgesics/antipyretics not 
elsewhere classified, anxiolytic/sedative/hypnotic, benzo-
diazepines, cyclo-oxygenase-2 inhibitors, muscle relaxants, 
nonsteroidal anti-inflammatory drugs, proton pump inhibi-
tors, strong opioids, and weak opioids. The order that the 
medication class was prescribed to new pain patients was 
examined as a proxy for line of therapy. Length of therapy 
was calculated as sum of days supply over the one-year 
study period.
The median total health care costs were also presented 
for each pain cohort. This was calculated using actual cash 
payments by the insurer for all costs related to the cost com-
ponents of pharmacy, emergency department, and inpatient 
and outpatient costs. These costs do not include copayments 
or deductibles paid by the insured. The median costs were also 
calculated and reported for each of these cost components. 
Further delineation was made as to whether these costs were 
associated with pain-related costs. Pain costs were defined 
as costs that were incurred during the same claim as any of 
the diagnoses associated with pain (listed in Table 1), and 
not only pain costs related to the index diagnosis (ie, the pain 
cohort of interest).
Results
Patient characteristics
Of the 23 specific pain conditions, low back pain (35.03%), 
osteoarthritis (30.14%), migraine (7.67%), and fibromy-
algia (6.24%) occurred most frequently. The least com-
monly reported condition was cancer pain, which included 
only 28 patients (0.00%). Women comprised the majority 
of each cohort in all but five conditions (% female), ie, 
phantom limb (28.78%), diabetic neuropathy (47.14%), 
human immunodeficiency virus (HIV)-associated pain 
(48.52%), psoriatic arthropathy (49.49%), and cancer 
pain (50.00%), as shown in Table 2. Conditions almost 
exclusively observed in women included painful bladder 
syndrome (98.29%), interstitial cystitis (88.2%), mul-
tiple sclerosis-associated neuropathic pain (81.30%), and 
migraine (81.19%).
Age of patients (mean ± standard deviation) in the 
specific pain cohorts ranged from 42.9 ± 12.78 years for 
migraine to 65.32 ± 15.74 years for stroke-associated 
neuropathic pain. There were differences observed in the 
prevalence of pain conditions in the 65 years and older age 
group. Some conditions were significantly less prevalent in 
the aged population, such as HIV-associated pain (0.27%), 
multiple sclerosis-associated pain (5.26%), complex 
regional pain syndrome (10.51%), migraine (4.25%), and 
painful bladder syndrome (8.08%). Conversely, there were 
other pain conditions that had a higher prevalence in those 
aged 65 years and older, such as postherpetic neuropathy 
(53.34%) and stroke-associated pain (52.22%). Variations 
across specific pain conditions were also found across indi-
cators of severity of illness using the Charlson Comorbidity 
Index and Chronic Disease Score. Across both indicators, 
migraine and painful bladder symptoms, cohorts had the 
least severe scores. Diabetic neuropathy, HIV-associated 
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Table 2 Demographic characteristics of pain condition cohorts
Characteristics Gender, %  
female
Age,  
mean (SD)
Age 65 years  
or older, %
CCIa  
mean (SD)
CDSb  
mean (SD)
Diabetic neuropathy (n = 37,133) 47.14 62.44 (12.57) 41.7 3.87 (1.78) 8.74 (3.44)
Postherpetic neuropathy (n = 3551) 60.1 65.21 (14.94) 53.34 1.03 (1.63) 6.42 (3.45)
Trigeminal neuralgia (n = 3869) 68.29 59.17 (15) 35.64 0.78 (1.41) 6.11 (3.32)
hIV-associated pain (n = 371) 48.52 44.3 (9.19) 0.27 7.04 (2.15) 6.09 (3.33)
Multiple sclerosis-associated pain (n = 647) 81.3 48.49 (11.45) 5.26 0.81 (1.43) 5.81 (3.26)
Stroke-associated pain (n = 3087) 58.47 65.32 (15.74) 52.22 2.65 (2.04) 7.17 (3.57)
Lumbar radiculopathy (n = 56,358) 56.82 53.97 (14.38) 21.71 0.68 (1.3) 5.74 (3.3)
Complex regional pain syndrome (n = 1808) 72.23 50.27 (12.84) 10.51 0.72 (1.28) 5.79 (3.27)
Spinal cord injury (n = 331) 48.34 51.91 (17.21) 20.54 1.1 (1.71) 6.09 (3.64)
Surgically-induced pain (n = 1478) 60.69 48.75 (16.17) 18.34 1.04 (1.95) 5.24 (3.13)
Phantom limb pain (n = 205) 28.78 56.43 (14.05) 28.29 1.9 (2.35) 7.02 (3.69)
Cervical radiculopathy (n = 40,844) 58.57 50.36 (12.48) 11.09 0.5 (1.09) 5.12 (3.02)
Fibromyalgia (n = 75,570) 70.07 50.44 (13.52) 12.32 0.61 (1.2) 5.36 (3.15)
Osteoarthritis (n = 365,086) 60.53 61.85 (13.39) 39.45 0.88 (1.45) 6.05 (3.34)
Low back pain (n = 424,410) 58.03 51.64 (15.79) 19.53 0.65 (1.32) 5.44 (3.22)
Migraine (n = 92,943) 81.19 42.9 (12.78) 4.25 0.37 (0.92) 4.75 (2.85)
Rheumatoid arthritis (n = 40,362) 72.75 57.88 (13.6) 29.26 1.71 (1.31) 6.96 (3.5)
Ankylosing spondylitis (n = 10,050) 60.73 52.74 (14.82) 19.6 0.63 (1.24) 5.54 (3.21)
Psoriatic arthropathy (n = 4795) 49.49 52.22 (12.19) 13.51 0.7 (1.16) 6.53 (3.38)
Cancer pain (n = 28) 50 53.07 (15.37) 17.86 6.07 (3.67) 7.11 (3.98)
Irritable bowel syndrome (n = 40,025) 75.2 49.49 (15.51) 15.71 0.47 (1.07) 4.84 (2.89)
Painful bladder syndrome (n = 2870) 98.29 44.28 (14.5) 8.08 0.44 (1.07) 4.63 (2.75)
Interstitial cystitis (n = 5662) 88.2 50.98 (15.25) 18.32 0.55 (1.14) 5.08 (2.95)
Notes: aCCI is a weighted composite measure that considers the presence of 16 diagnoses present in claims data; bCDS is a weighted composite score derived from the 
presence of drug claim for specific medication classes. 
Abbreviations: HIV, human immunodeficiency virus; CCI, Charlson Comorbidity Index; CDS, Chronic Disease Score; SD, standard deviation.
pain, and cancer pain cohorts were among those with the 
highest severity scores.
Comorbid pain conditions
Patients in this sample tended to have more than one concur-
rent painful condition. Of the 23 pain condition cohorts, the 
mean number of pain conditions claimed during the study 
period ranged from 1.39 (migraine, cancer pain) to 2.65 
(multiple sclerosis-associated pain), as shown in Table 3. 
Overall conditions related to neuropathic pain tended to have 
the highest mean number of pain-related comorbidities, ie, 
multiple sclerosis pain (2.65), spinal cord injury (2.58), and 
HIV-associated pain (2.50).
Table 3 presents the percentage of patients within each pain 
cohort with a claim for another pain category or condition. 
Analogous with the prevalence rates of the pain categories and 
condition cohorts, comorbidity rates for each of the 23 pain 
condition cohorts were highest for the musculoskeletal category 
(including low back pain, osteoarthritis, and fibromyalgia) fol-
lowed by the neuropathic pain category (led by stroke pain and 
radiculopathy conditions). Cancer pain and phantom limb pain 
were the least frequently reported pain comorbidities.
Comorbid mental health and sleep 
disorders
The presence of mental health and sleep comorbidities were 
described using multiple indicators, including percentage of 
patients with any mental health condition, mean number of 
mental health conditions, and percentage of patients with 
major depressive disorder, other depressive symptoms, 
anxiety, and other psychiatric conditions (Table 4). Rates of 
mental health comorbidities were also assessed across pain 
condition cohorts. The results indicate that pain conditions 
are comorbid with mental health conditions, but it should 
not be interpreted that this comorbidity means that there is 
a causal association between pain and mental health condi-
tions. In general, HIV-associated pain and multiple sclerosis-
associated pain were consistently among the pain conditions 
with the highest rates of mental health comorbidities. Other 
conditions with high rates included cancer pain, spinal cord 
injury, stroke-associated pain, and phantom limb pain.
The three pain conditions with the highest number of 
mental health comorbidities were HIV-associated pain 
(42.59%), phantom limb (36.10%), and multiple sclerosis-
associated pain (34.78%). The conditions with the lowest 
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percentage having at least one comorbid mental health 
condition were found for postherpetic neuralgia (14.81%), 
psoriatic arthropathy (13.31%), and rheumatoid arthritis 
(12.73%). The conditions with the highest mean number 
of mental health comorbidities were HIV-associated pain 
(1.82) and multiple sclerosis-associated pain (1.71). The 
conditions with the lowest mean number of mental health 
comorbidities were rheumatoid arthritis (1.32) and psoriatic 
arthropathy (1.30).
The condition with the greatest percentage of patients 
who had major depressive disorder was the HIV-associated 
pain cohort (14.02%), while the lowest percentage was 
observed in the postherpetic neuralgia group (2.99%). “Other 
depressive symptoms” was also highest in the HIV-associated 
pain group (21.02%), while the lowest percentage was found 
in the rheumatoid arthritis cohort (2.81%). Other psychiatric 
disorders, excluding depression and anxiety, were highest 
in stroke-associated pain patients (18.21%) and lowest for 
psoriatic arthropathy patients (2.82%). Anxiety had the 
greatest prevalence in the multiple sclerosis-associated pain 
cohort (12.83%) and was lowest in the rheumatoid arthritis 
cohort (3.59%).
The percentage of patients with sleep disorders ranged 
from 5.47% in the painful bladder symptom cohort to 11.59% 
in the multiple sclerosis-associated pain cohort, as shown 
in Table 4.
Pain medications
Most patients with pain were prescribed at least one pain 
pharmacotherapy during the one-year study period, with 
a minimum of 70.46% (in the irritable bowel syndrome 
cohort) of patients across the cohorts being prescribed at 
least one pharmacotherapy (Table 5). The median length 
of therapy was much more diverse across pain categories, 
with the shortest duration of therapy occurring among the 
surgically-induced pain cohort (41 days) and several groups 
with supplies lasting all 365 days, including cohorts with 
HIV-associated pain, multiple sclerosis-associated pain, 
complex regional pain syndrome, phantom limb pain, and 
cancer pain.
Across the 23 pain conditions, variability in prescribed 
pain medications was observed. The cohort with the largest 
percentage of patients taking at least one pharmacotherapy 
was phantom limb pain (92.2%). The number of unique 
medications prescribed was examined across the cohorts. 
The cancer pain cohort was prescribed the greatest mean 
number of unique medications (5.36 ± 2.75), while psori-
atic arthropathy was prescribed the lowest mean number 
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of unique   medications (2.76 ± 2.06). Opioid medications, 
primarily strong opioids, were the most common medication 
used for all pain conditions, except for trigeminal neuralgia 
where anticonvulsants were used more frequently. The second 
most prescribed drug was antidepressants for all three visceral 
pain conditions (irritable bowel syndrome, painful bladder 
symptoms, and interstitial cystitis), cancer pain, migraine, 
and fibromyalgia and nonsteroidal anti-inflammatory 
drugs for all inflammatory arthritis conditions (rheumatoid 
arthritis, ankylosing spondylitis, and psoriatic arthropathy), 
osteoarthritis, and low back pain. The second most prescribed 
medication varied across neuropathic pain conditions, with 
antidepressants prescribed more often for diabetic neuropa-
thy, HIV-associated pain, multiple sclerosis-associated pain, 
stroke-associated pain, and complex regional pain syndrome. 
Nonsteroidal anti-inflammatory drugs were more often pre-
scribed for lumbar and cervical radiculopathies, spinal cord 
injury, and surgically-induced pain. Anticonvulsants were 
more often prescribed for postherpetic neuralgia, trigeminal 
neuralgia, and phantom limb pain.
We also assessed what type of medication was prescribed 
first following the index pain diagnosis. Across all 23 pain 
cohorts, the therapies most commonly prescribed as first-
line were anticonvulsants/antiepileptics, antidepressants, 
nonsteroidal anti-inflammatory drugs, and strong opioids. 
Again, opioids were most commonly the first-line therapy for 
patients, including the majority of neuropathic pain condition 
cohorts (HIV-associated pain, multiple sclerosis-associated 
pain, stroke pain, lumbar and cervical radiculopathy, com-
plex regional pain syndrome, spinal cord injury, surgically-
induced pain, phantom limb pain), and cancer pain, as well as 
painful bladder symptoms, interstitial cystitis, osteoarthritis, 
low back pain, and ankylosing spondylitis. Antidepressants 
were first-line for cohorts with diabetic neuropathy, fibromy-
algia, migraine, and irritable bowel syndrome. Nonsteroidal 
anti-inflammatory drugs were first-line for cohorts with 
rheumatoid arthritis and psoriatic arthropathy. Anticonvul-
sants were first-line for cohorts with postherpetic neuralgia 
and trigeminal neuralgia.
Annual medical and drug costs
Costs were examined by looking at total median annual health 
care costs, including inpatient, outpatient, pharmaceutical, 
and emergency room costs (Figure 1). These cost compo-
nents were further examined by looking at costs incurred in 
conjunction with pain diagnosis-related services, and costs 
in the absence of a pain diagnosis. Pain-related costs were 
defined as costs that were coded for any pain condition as 
listed in Table 1. Therefore, pain costs presented in Figure 2 
are not necessarily related to the primary diagnosed condi-
tion, and could reflect the cost of a comorbid pain condition. 
Consistently, cancer pain most commonly had the highest 
costs across the cost components examined. The cohorts 
with the lowest costs were less consistent across the cost 
components and most commonly included the postherpetic 
neuralgia, migraine, surgically-induced pain, and irritable 
bowel syndrome cohorts.
Overall, the highest median total costs were found in cancer 
pain ($56,404.15). The cancer pain cohort also had the highest 
total median inpatient ($25,530.43), outpatient ($20,363.26), 
and emergency room ($1,436.96) costs. However, the HIV-
associated pain cohort had the highest median total pharmaceu-
tical costs ($13,276.81). The migraine cohort had the lowest 
overall total median costs ($4855.38), as well as the lowest 
total outpatient median costs ($2102.30). The cohort with the 
lowest total inpatient costs ($7584.18) and total emergency 
room costs ($416.45) was the postherpetic neuralgia cohort. 
The lowest median pharmaceutical costs were observed in the 
surgically-induced pain cohort ($967.16).
When examining pain-related cost components, the mul-
tiple sclerosis-associated pain cohort had the highest costs 
for both pain-related total costs ($4011.12) and pain-related 
outpatient costs ($3030.45). Irritable bowel syndrome had 
the lowest total pain-related ($151.28) and outpatient pain-
related costs ($143.81). Inpatient pain-related costs were 
highest for HIV-associated pain patients ($11,862.32) and 
lowest for surgically-induced pain patients ($218.54). The 
cancer pain cohort had the highest costs across all the 
  nonpain-related cost components (total $42,673.92), ie, inpa-
tient ($25,148. 90), outpatient ($18,993.56), and emergency 
room ($1234.27) costs. However, the lowest nonpain-related 
costs were varied across the pain conditions. The lowest total 
nonpain-related costs were observed in psoriatic arthropathy 
($1867.16). The multiple sclerosis associated-pain cohort had 
the lowest inpatient nonpain-related costs ($4613.97). HIV-
associated pain had the lowest outpatient nonpain-related 
costs ($1674.09). The postherpetic neuralgia cohort had the 
lowest emergency room nonpain-related costs ($374.35).
Discussion
The objectives of this study were to characterize the rates of 
comorbidity, pain medication use, and health care costs for 
selected pain conditions. This analysis illustrates the high 
levels of comorbidities faced by patients with pain. Rates 
of comorbid conditions related to pain, mental health, and 
sleep-related disorders are shown for the 23 conditions from 
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Table 5 Pain medication use by selected pain condition cohorts
Patients 
taking 1 
pharmacotherapy 
(%)
Unique  
drugs, %   
(Mean,  
SD)
Length of  
therapy  
(median  
days)
Analgesics/ 
antipyretics,   
NECa
Anticonvulsants/ 
Antiepileptics
SNRIb SSRIc TCAsd Other  
antidepressants
Total  
antidepressants
Anxiolytics/ 
sedatives/  
hypnotics  
NEC
Benzodiazepines COX-2e  
inhibitors
Muscle  
Relaxants
NSAIDsf Strong  
opioids
Total  
weak  
opioids
Total opioid  
use (weak  
and strong)
Triptans
Diabetic  
neuropathy  
(n = 37,133)
74.00 3.13  
(2.33)
297.00 1.08 25.21 8.13 18.40 10.55 7.10 34.26* 12.68 18.62 4.11 10.53 24.29 37.60 18.55 46.30 0.06
Postherpetic  
neuropathy  
(n = 3551)
84.15 3.33  
(2.37)
245.50 1.04 51.25* 8.65 15.46 15.91 5.32 36.19 15.49 20.61 4.90 9.55 20.05 46.66 20.36 55.53 0.34
Trigeminal  
neuralgia  
(n = 3869)
87.59 3 (2) 300.00 2.04 61.00* 8.12 16.85 10.75 6.36 33.37 13.62 23.47 3.75 12.72 24.86 43.24 18.04 50.87 0.65
hIV-associated 
pain (n = 371)
86.79 5.08  
(3.26)
376.00 5.39 21.29 9.70 28.57 20.49 20.49 50.13 28.84 29.38 2.96 20.75 51.48 66.31* 23.99 69.54 0.81
Multiple  
sclerosis- 
associated  
pain (n = 647)
86.71 4.73  
(3.31)
480.00 3.09 37.25 19.01 32.77 16.54 15.92 57.50* 23.49 37.56 3.71 31.07 29.52 49.30 26.28 58.89 1.85
Stroke- 
associated  
pain (n = 3087)
81.18 3.48  
(2.55)
270.00 4.18 18.37 8.71 26.89 9.62 7.97 41.04* 17.30 28.02 5.96 15.81 24.81 42.92* 25.53 54.84 0.65
Lumbar  
radiculopathy  
(n = 56,358)
79.22 3.76  
(2.76)
240.00 1.64 18.86 7.79 17.69 7.59 7.95 31.14 14.95 23.99 6.94 27.53 34.67 50.12* 22.61 58.51 0.38
Complex  
regional pain  
syndrome  
(n = 1808)
90.65 5.00  
(2.98)
632.00 2.38 48.56 20.24 25.72 21.57 16.65 56.86 23.34 35.90 6.03 26.16 30.97 69.58* 23.51 76.38 0.55
Spinal cord  
injury (n = 331)
86.71 4.14  
(2.80)
215.00 0.91 23.26 12.39 19.34 7.55 11.48 35.95 18.43 28.40 3.93 32.02 36.86 64.35* 23.87 71.00 0.30
Surgically  
induced pain 
(n = 1478)
90.26 2.99  
(2.23)
41.00 1.89 5.48 4.74 15.63 3.52 5.21 23.00 15.70 16.31 5.07 10.15 32.81 79.57* 20.91 84.44 0.14
Phantom limb  
(n = 205)
92.20 5.05  
(3.17)
720.00 0.49 60.49 19.51 19.02 23.41 11.71 51.22 25.37 33.17 2.44 20.49 28.29 80.00* 20.00 82.93 –
Cervical  
radiculopathy  
(n = 40,844)
74.94 3.48  
(2.57)
157.00 2.00 13.45 6.67 17.14 6.04 7.79 29.09 13.88 21.47 5.32 26.77 33.77 43.35* 18.24 50.51 0.56
Fibromyalgia  
(n = 75,570)
77.28 3.81  
(2.83)
273.00 2.46 13.33 12.29 21.71 10.40 11.52 39.71* 17.81 24.87 5.38 27.95 34.34 40.03 21.33 49.52 0.64
Osteoarthritis  
(n = 365,086)
79.91 3.19  
(2.30)
226.00 1.35 9.47 5.68 17.16 5.92 6.65 27.89 14.11 20.19 10.21 15.49 38.10 45.23* 23.70 55.48 0.26
Low back pain  
(n = 424,410)
79.32 3.54  
(2.57)
150.00 1.77 10.67 6.43 17.52 6.11 7.65 28.78 13.44 21.89 5.31 33.11 38.09 47.24* 21.50 55.84 0.36
Migraine  
(n = 92,943)
80.09 3.71  
(2.91)
229 9.77 22.28 9.86 23.22 14.01 10.76 42.33* 16.43 23.77 2.57 19.87 31.55 41.93 17.35 48.28 6.33
Rheumatoid  
arthritis  
(n = 40,362)
79.73 2.98  
(2.22)
410 1.34 8.54 5.79 16.72 6.58 6.53 28.16 13.54 17.50 11.54 13.94 40.24* 38.05 22.95 49.71 0.33
Ankylosing  
spondylitis  
(n = 10,050)
78.44 3.51  
(2.58)
267.00 1.60 10.92 7.70 18.09 6.72 8.32 30.84 15.01 21.82 7.99 25.17 39.84 42.77* 21.85 52.35 0.50
Psoriatic  
arthropathy  
(n = 4795)
75.60 2.76  
(2.06)
287.00 0.92 6.19 5.86 16.96 5.15 7.74 27.90 12.49 15.45 9.47 12.05 40.77* 32.30 16.89 41.42 0.17
Cancer pain  
(n = 28)
78.57 5.36  
(2.75)
399.5 7.14 28.57 7.14 28.57 17.86 21.43 46.43 21.43 28.57 3.57 14.29 14.29 67.86* 25.00 71.43 3.57
(Continued)
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Table 5 Pain medication use by selected pain condition cohorts
Patients 
taking 1 
pharmacotherapy 
(%)
Unique  
drugs, %   
(Mean,  
SD)
Length of  
therapy  
(median  
days)
Analgesics/ 
antipyretics,   
NECa
Anticonvulsants/ 
Antiepileptics
SNRIb SSRIc TCAsd Other  
antidepressants
Total  
antidepressants
Anxiolytics/ 
sedatives/  
hypnotics  
NEC
Benzodiazepines COX-2e  
inhibitors
Muscle  
Relaxants
NSAIDsf Strong  
opioids
Total  
weak  
opioids
Total opioid  
use (weak  
and strong)
Triptans
Diabetic  
neuropathy  
(n = 37,133)
74.00 3.13  
(2.33)
297.00 1.08 25.21 8.13 18.40 10.55 7.10 34.26* 12.68 18.62 4.11 10.53 24.29 37.60 18.55 46.30 0.06
Postherpetic  
neuropathy  
(n = 3551)
84.15 3.33  
(2.37)
245.50 1.04 51.25* 8.65 15.46 15.91 5.32 36.19 15.49 20.61 4.90 9.55 20.05 46.66 20.36 55.53 0.34
Trigeminal  
neuralgia  
(n = 3869)
87.59 3 (2) 300.00 2.04 61.00* 8.12 16.85 10.75 6.36 33.37 13.62 23.47 3.75 12.72 24.86 43.24 18.04 50.87 0.65
hIV-associated 
pain (n = 371)
86.79 5.08  
(3.26)
376.00 5.39 21.29 9.70 28.57 20.49 20.49 50.13 28.84 29.38 2.96 20.75 51.48 66.31* 23.99 69.54 0.81
Multiple  
sclerosis- 
associated  
pain (n = 647)
86.71 4.73  
(3.31)
480.00 3.09 37.25 19.01 32.77 16.54 15.92 57.50* 23.49 37.56 3.71 31.07 29.52 49.30 26.28 58.89 1.85
Stroke- 
associated  
pain (n = 3087)
81.18 3.48  
(2.55)
270.00 4.18 18.37 8.71 26.89 9.62 7.97 41.04* 17.30 28.02 5.96 15.81 24.81 42.92* 25.53 54.84 0.65
Lumbar  
radiculopathy  
(n = 56,358)
79.22 3.76  
(2.76)
240.00 1.64 18.86 7.79 17.69 7.59 7.95 31.14 14.95 23.99 6.94 27.53 34.67 50.12* 22.61 58.51 0.38
Complex  
regional pain  
syndrome  
(n = 1808)
90.65 5.00  
(2.98)
632.00 2.38 48.56 20.24 25.72 21.57 16.65 56.86 23.34 35.90 6.03 26.16 30.97 69.58* 23.51 76.38 0.55
Spinal cord  
injury (n = 331)
86.71 4.14  
(2.80)
215.00 0.91 23.26 12.39 19.34 7.55 11.48 35.95 18.43 28.40 3.93 32.02 36.86 64.35* 23.87 71.00 0.30
Surgically  
induced pain 
(n = 1478)
90.26 2.99  
(2.23)
41.00 1.89 5.48 4.74 15.63 3.52 5.21 23.00 15.70 16.31 5.07 10.15 32.81 79.57* 20.91 84.44 0.14
Phantom limb  
(n = 205)
92.20 5.05  
(3.17)
720.00 0.49 60.49 19.51 19.02 23.41 11.71 51.22 25.37 33.17 2.44 20.49 28.29 80.00* 20.00 82.93 –
Cervical  
radiculopathy  
(n = 40,844)
74.94 3.48  
(2.57)
157.00 2.00 13.45 6.67 17.14 6.04 7.79 29.09 13.88 21.47 5.32 26.77 33.77 43.35* 18.24 50.51 0.56
Fibromyalgia  
(n = 75,570)
77.28 3.81  
(2.83)
273.00 2.46 13.33 12.29 21.71 10.40 11.52 39.71* 17.81 24.87 5.38 27.95 34.34 40.03 21.33 49.52 0.64
Osteoarthritis  
(n = 365,086)
79.91 3.19  
(2.30)
226.00 1.35 9.47 5.68 17.16 5.92 6.65 27.89 14.11 20.19 10.21 15.49 38.10 45.23* 23.70 55.48 0.26
Low back pain  
(n = 424,410)
79.32 3.54  
(2.57)
150.00 1.77 10.67 6.43 17.52 6.11 7.65 28.78 13.44 21.89 5.31 33.11 38.09 47.24* 21.50 55.84 0.36
Migraine  
(n = 92,943)
80.09 3.71  
(2.91)
229 9.77 22.28 9.86 23.22 14.01 10.76 42.33* 16.43 23.77 2.57 19.87 31.55 41.93 17.35 48.28 6.33
Rheumatoid  
arthritis  
(n = 40,362)
79.73 2.98  
(2.22)
410 1.34 8.54 5.79 16.72 6.58 6.53 28.16 13.54 17.50 11.54 13.94 40.24* 38.05 22.95 49.71 0.33
Ankylosing  
spondylitis  
(n = 10,050)
78.44 3.51  
(2.58)
267.00 1.60 10.92 7.70 18.09 6.72 8.32 30.84 15.01 21.82 7.99 25.17 39.84 42.77* 21.85 52.35 0.50
Psoriatic  
arthropathy  
(n = 4795)
75.60 2.76  
(2.06)
287.00 0.92 6.19 5.86 16.96 5.15 7.74 27.90 12.49 15.45 9.47 12.05 40.77* 32.30 16.89 41.42 0.17
Cancer pain  
(n = 28)
78.57 5.36  
(2.75)
399.5 7.14 28.57 7.14 28.57 17.86 21.43 46.43 21.43 28.57 3.57 14.29 14.29 67.86* 25.00 71.43 3.57
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Table 5 (Continued)
Patients 
taking 1 
pharmacotherapy 
(%)
Unique  
drugs, %   
(Mean,  
SD)
Length of  
therapy  
(median  
days)
Analgesics/ 
antipyretics,   
NECa
Anticonvulsants/ 
Antiepileptics
SNRIb SSRIc TCAsd Other 
antidepressants
Total  
antidepressants
Anxiolytics/ 
sedatives/  
hypnotics  
NEC
Benzodiazepines COX-2e  
inhibitors
Muscle  
Relaxants
NSAIDsf Strong  
opioids
Total  
weak  
opioids
Total opioid  
use (weak  
and strong)
Triptans
Irritable bowel  
syndrome  
(n = 40,025)
70.46 2.98  
(2.30)
188.00 2.30 6.27 7.33 22.85 9.47 9.14 37.32* 14.86 25.04 3.22 12.65 22.48 30.30 14.27 37.34 0.50
Painful bladder  
syndrome  
(n = 2870)
76.10 3.17  
(2.40)
95.00 2.40 6.17 6.76 20.52 8.68 8.57 34.60 16.24 21.57 2.47 12.16 32.54 44.15* 18.40 51.43 0.73
Interstitial  
cystitis  
(n = 5662)
80.36 3.59  
(2.70)
270.00 2.17 11.20 8.85 20.24 21.25 9.64 44.68* 28.12 27.18 4.24 15.61 26.09 43.24 22.18 51.94 0.67
Note: *Most common therapy prescribed as first-line for cohort. 
Abbreviations: A, not elsewhere classified; B, serotonin norepinephrine reuptake inhibitors; C, selective serotonin reuptake inhibitors; D, tricyclic antidepressants; E, cyclo-
oxygenase; F, nonsteroidal anti-inflammatory drugs; HIV, human immunodeficiency virus; SD, standard deviation.
$0
Diabetic neuropathy
Postherpetic neuralgia
Trigeminal neuralgia
HIV pain
Multiple sclerosis
Stroke pain
Lumbar radiculopathy
Complex regional pain syndrome
Spinal cord injury
Surgically induced
Phantom limb
Cervical radiculopathy
Fibromyalgia
Osteoarthritis
Low back pain
Migraine
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthropathy
Cancer pain
Irritable bowel syndrome
Painful bladder syndrome
Interstitial cystitis
$10,000
$20,000
$30,000
$40,000
$50,000
$60,000
Figure 1 Total annual median costs for all medical and drug use by pain condition cohorts.
a large health plan using administrative health claims data. 
The findings of this study are consistent with previous litera-
ture that aims to characterize rates of comorbid   conditions. 
  Conditions do often occur together, whether they are physi-
cal, painful, or mental. Most patients tend to have more than 
one pain condition, so the term “chronic pain” should be 
used with caution because conditions do tend to vary across 
patient populations and treatment patterns.
Understanding the rate of comorbidity for specific pain 
conditions may aid in the interpretation of study findings 
that lack distinct classification of “chronic pain” or that 
exclude subjects who have comorbid conditions in an effort 
to reduce bias and confounding. These findings may be used 
as a resource for clinical and research fields to understand the 
variability among patients who experience pain. According 
to the International Pain Society, pain management is inade-
quate in most of the world because: there are major deficits in 
knowledge on the part of health care professionals regarding 
the mechanisms and management of pain; there is inadequate 
access to treatment and failure to recognize the necessity for 
access to management akin to other chronic diseases such 
as diabetes or chronic heart disease; most countries have no 
national policy at all or very inadequate policies regarding 
management of pain as a health problem, including an inad-
equate level of research and education; and pain medicine is 
not recognized as a distinct specialty with a unique body of 
knowledge and defined scope of practice founded on research 
and comprehensive training programs.21 The Institute of 
Medicine has called for a cultural transformation regarding 
pain care.2 In order to achieve this transformation, the Insti-
tute of Medicine plan requests development of a national 
population-based prevention/management strategy, a more 
tailored approach to treatment, and a strategy to reduce or 
remove the barriers which limit access to care.2
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Table 5 (Continued)
Patients 
taking 1 
pharmacotherapy 
(%)
Unique  
drugs, %   
(Mean,  
SD)
Length of  
therapy  
(median  
days)
Analgesics/ 
antipyretics,   
NECa
Anticonvulsants/ 
Antiepileptics
SNRIb SSRIc TCAsd Other 
antidepressants
Total  
antidepressants
Anxiolytics/ 
sedatives/  
hypnotics  
NEC
Benzodiazepines COX-2e  
inhibitors
Muscle  
Relaxants
NSAIDsf Strong  
opioids
Total  
weak  
opioids
Total opioid  
use (weak  
and strong)
Triptans
Irritable bowel  
syndrome  
(n = 40,025)
70.46 2.98  
(2.30)
188.00 2.30 6.27 7.33 22.85 9.47 9.14 37.32* 14.86 25.04 3.22 12.65 22.48 30.30 14.27 37.34 0.50
Painful bladder  
syndrome  
(n = 2870)
76.10 3.17  
(2.40)
95.00 2.40 6.17 6.76 20.52 8.68 8.57 34.60 16.24 21.57 2.47 12.16 32.54 44.15* 18.40 51.43 0.73
Interstitial  
cystitis  
(n = 5662)
80.36 3.59  
(2.70)
270.00 2.17 11.20 8.85 20.24 21.25 9.64 44.68* 28.12 27.18 4.24 15.61 26.09 43.24 22.18 51.94 0.67
Note: *Most common therapy prescribed as first-line for cohort. 
Abbreviations: A, not elsewhere classified; B, serotonin norepinephrine reuptake inhibitors; C, selective serotonin reuptake inhibitors; D, tricyclic antidepressants; E, cyclo-
oxygenase; F, nonsteroidal anti-inflammatory drugs; HIV, human immunodeficiency virus; SD, standard deviation.
$0
Diabetic neuropathy
Postherpetic neuralgia
Trigeminal neuralgia
HIV pain
Multiple sclerosis
Stroke pain
Lumbar radiculopathy
Complex regional pain syndrome
Spinal cord injury
Surgically induced
Phantom limb
Cervical radiculopathy
Fibromyalgia
Osteoarthritis
Low back pain
Migraine
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthropathy
Cancer pain
Irritable bowel syndrome
Painful bladder syndrome
Interstitial cystitis
$1,000
$2,000
$3,000
$4,000
$5,000
Figure 2 Annual median pain-related medical costs by pain condition cohorts.
The cohort with the highest mean number of comorbid 
pain conditions was in the multiple sclerosis-associated pain 
(2.65) cohort, while the lowest mean number of comorbid 
pain conditions was observed in the cancer pain and migraine 
cohorts (1.39). Thus, multiple sclerosis has a higher comor-
bidity with other pain conditions when compared with cancer 
pain and migraine.
There was a large sample size available for use in the cur-
rent study from the MarketScan database. This reaffirms that 
pain conditions and comorbid mental health conditions are 
quite prominent in this population, and more research should 
be done to enhance treatment and understanding, particularly 
in the comorbid patient, because this study showed a range 
of mean comorbid pain conditions of 1.39–2.65.
Almost all patients in the sample were taking a pain 
medication and many were taking more than one type of pain 
medication, while the type of medications prescribed across 
the cohorts varied. Surprisingly, opioid medication use was 
consistently prescribed first in the claims data across all pain 
conditions. The average number of unique medications was 
3.53 ± 2.58 across the sample. These findings suggest that 
these conditions (and their comorbidities) are a high burden 
to patients. The burden to the patients exists in both suffering 
from painful conditions, but also in having to take several 
medications to manage the pain.
The study demonstrates that the majority of the 23 pain 
conditions affect women more frequently, which is consistent 
with previous pain studies. However, this study found that 
there were notable differences across the disease states. Also 
in line with previously published studies, pain conditions 
usually affect those in the middle-aged and older groups, 
but again differences were found in selected pain states.4 
Older patients generally are more likely to experience pain 
as a result of diseases that are typically found in an older 
population, such as stroke. Again, costs were varied across 
the pain cohorts. Some cohorts had much higher costs than 
others. The cost components examined show the variety in 
pain-related costs and nonpain-related costs. The conditions 
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with the highest pain-related costs across the cost components 
examined (inpatient, outpatient, and emergency room) were 
multiple sclerosis-associated pain and HIV-associated pain. 
This finding suggests a large portion of health care dollars 
is used to treat the pain component of these debilitating 
illnesses. Across the pain conditions, approximately 20% 
of total visits were to an emergency room, thus increasing 
costs. Resource utilization in general and for pain could 
be avoided/reduced if the patient was being well managed 
pharmacologically by a primary care physician.
There are some limitations to using claims data, includ-
ing difficulty generalizing to a noninsured population, 
miscoding due to administrative causes such as making a 
diagnosis fit a billing requirement or sometimes choosing 
the code that obtains the greater payment.22 Although many 
pain conditions are chronic, ICD-9 codes do not include the 
chronicity of the illness in the diagnosis. This study limited 
the scope of comorbidities to other pain, mental health, and 
sleep-related diagnoses. Other studies have found that other 
physical comorbidities, such as hypertension or heart disease, 
are commonly reported by patients with pain. If this had 
been examined, an even greater burden would be present, 
but this has been shown by previous literature. The patients 
were also put into categories somewhat arbitrarily if they had 
other pain comorbidities, as mentioned in the study sample 
and cohorts section. Further, there were so many comorbid 
patients that we could not determine whether costs/prescrip-
tion medication use is driven by the primary diagnosis or one 
of the other diagnoses.
Claims data may also underrepresent mental health con-
ditions. Data from 2005 indicate the 12-month prevalence 
of mental disorder to be 29.1% among US adults.23 In this 
sample, the prevalence of any mental health comorbidity 
was 18%. Previous data have shown that at least 10% of 
the US population has a sleep disorder.24 In this sample, the 
prevalence of any sleep disorder was 7.7%. Therefore, the 
comorbiditiy of pain and mental health may be even higher 
than what is reported in claims.
Pain conditions are often difficult to diagnose properly. 
This could potentially affect the dataset because one provider 
may have provided a different diagnosis than a second pro-
vider and this could be reflected as a comorbid condition. 
According to Dworkin et al, some physicians were coding 
only that a patient was seen for herpes zoster, when the patient 
may have also presented with postherpetic neuropathy.25 
This could lead to an underestimate of the prevalence of pain 
conditions that are related to other health conditions in the 
population under study.
The majority of patients in this study were prescribed 
pain medications. This does not include any over the 
counter pain medications, medications purchased without 
use of insurance, or free samples provided by physicians. 
We were able to determine which pain conditions had the 
highest number of unique pain medications, as well as what 
medication classes were prescribed as first, second, and 
third in the insurance claims across the different conditions. 
According to a synthesis of the available literature on treat-
ment of pain, the best practices for prescribing medications 
should be based on the type of pain, and each pain condition 
should be treated as unique.26 Our findings are consistent 
with those of Kroenke et al, ie, that patients are generally 
started on different first-line therapies based on the type 
of pain they are experiencing.26 According to the recent 
Institute of Medicine recommendations, treatment strategies 
should be tailored to each patient as opposed to following 
a standardized, stepped approach.2 Opioids were the first 
prescribed medication for the majority of the neuropathic 
pain cohorts. Nonsteroidal anti-inflammatory drugs were 
prescribed first-line for patients with rheumatoid arthritis 
and psoriatic arthropathy, although the guidance suggests 
nonsteroidal anti-inflammatory drugs should be prescribed 
first-line for most pain conditions. Prescription of antidepres-
sants and anticonvulsants were generally consistent with the 
recommendations.
This study demonstrated how costly these pain condi-
tions can be to treat. In the sample, there were high costs 
that varied across the pain cohorts. The cost analysis in this 
study provides information about the original illness causing 
the pain to occur. For example, cancer pain had the highest 
median costs overall. In this example, costs are likely driven 
by the costs of treating the cancer. Interestingly, some of the 
conditions that had the highest pain-related costs had the 
lowest nonpain-related costs, such as the multiple sclerosis-
associated pain and HIV-associated pain cohorts. This finding 
suggests that a large portion of the cost to treat these patients 
is due to pain. Cancer pain had the highest emergency room 
pain-related costs ($936.48), while osteoarthritis had the 
lowest emergency room pain-related costs ($180.57). This 
finding suggests that cancer pain is acute and severe, while 
osteoarthritis is chronic and does not generally result in an 
emergency room visit for treatment. While the current study 
looked at pain-related and nonpain-related cost components, 
further research could be done with respect to costs to deter-
mine what costs are incurred for treating the initial conditions 
and then examine what proportion of costs the comorbid 
conditions contribute to the overall costs.
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The comorbid patient continually presents a challenge 
to treating physicians. This research highlights the burden, 
incidence, and costs of pain in patients with comorbid con-
ditions. The body of research on comorbidities continues to 
grow. Improving care for each patient by taking a holistic 
approach to their treatment that encompasses not only the 
pain condition the patient is currently presenting with, but 
also their mental health and other pain conditions, is a poten-
tial way to drive health care costs downward and ultimately 
improve outcomes.
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